We hypothesize there are coagulation profile changes associated both with @entity1613 (TPX) and with change in platelet levels in @entity130 @entity1 at high-risk for @entity1211 ( @entity1211 ). A total of 1203 @entity130 intensive care unit @entity1 were screened with a @entity1211 risk assessment profile. In all, 302 high-risk @entity1 (risk assessment profile score >=  10) were consented for weekly thromboelastography. TPX was initiated between initial and follow-up thromboelastography. Seventy-four @entity1 were analyzed. Upon admission, 87 per cent were hypercoagulable, and 81 per cent remained hypercoagulable by Day 7 (P = 0.504). TPX was initiated 3.4    1.4 days after admission; 68 per cent received unfractionated heparin and 32 per cent received low-molecular-weight heparin. The @entity1211 rate was 18 per cent, length of stay 38 (25-37) days, and mortality of 17.6 per cent. In all, 76 per cent had a rapid clotting time at admission versus 39 per cent at Day 7 (P < 0.001); correcting from 7.75 (6.45-8.90) minutes to 10.45 (7.90-15.25) minutes (P < 0.001). At admission, 41 per cent had an elevated @entity4461 ( @entity4461 ) and 85 per cent had at Day 7 (P < 0.001); increasing from 61(55-65) mm to 75(69-80) mm (P < 0.001). Platelets positively correlated with @entity4461 at admission (r = 0.308, R(2) = 0.095, P = 0.008) and at Day 7 (r = 0.516, R(2) = 0.266, P < 0.001). Change in platelet levels correlated with change in @entity4461 (r = 0.332, R(2) = 0.110, P = 0.005). In conclusion, @entity49 persists despite the use of TPX. Although clotting time normalizes, @entity4461 increases in correlation with platelet levels. As platelet function is a dominant contributor to sustained @entity130 -evoked @entity49 , antiplatelet therapy may be indicated in the management of severely injured @entity130 @entity1 .

Coagulation Profile Changes Due to Thromboprophylaxis and Platelets in @entity130 XXXX at High-Risk for @entity1211 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity49 :: ('MESH:D019851', 'Disease') :: ['hypercoagulability'] @entity4461 :: ('MESH:D020141', 'Disease') :: ['MCF', 'maximum clot formation'] @entity1613 :: ('MESH:D011230', 'Disease') :: ['initiation of thromboporphylaxis'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma']
@entity1 :: (9606,Species) :: ['Patients']
